Disc Medicine, Inc. (IRON) Stock
IRON has an Alpha Score of 41 out of 100 (weak), computed on Aug 23, 2026 from 2 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported IRON in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $15.31M. Company insiders reported 0 open-market buys and 32 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
What is IRON's Alpha Score?
How it works →Alpha Score of 41 reflects weak overall profile with moderate momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Aug 23, 2026 · 60 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own IRON?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 209K | $15.31M | +114% |
| Millennium Management Israel Englander | 106K | $7.77M | +28% |
| Marshall Wace | 34K | $2.52M | NEW |
| D.E. Shaw David Shaw | 6K | $440.8K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Disc Medicine, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 21, 26 | Bitterman Kevin | Director | SELL | 13.8K | $1.1M |
| Oct 21, 26 | Bitterman Kevin | Director | SELL | 11.5K | $920K |
| Oct 21, 26 | Bitterman Kevin | Director | SELL | 266 | $21K |
| Oct 20, 26 | Bitterman Kevin | Director | SELL | 2.9K | $229K |
| Oct 20, 26 | Bitterman Kevin | Director | SELL | 2.4K | $191K |
| Oct 20, 26 | Bitterman Kevin | Director | SELL | 55 | $4K |
| Oct 19, 26 | Bitterman Kevin | Director | SELL | 5.9K | $475K |
| Oct 19, 26 | Bitterman Kevin | Director | SELL | 4.9K | $395K |
| Oct 19, 26 | Bitterman Kevin | Director | SELL | 115 | $9K |
| Sep 11, 26 | Bitterman Kevin | Director | SELL | 27.1K | $1.9M |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →What are IRON's key statistics?
Key statistics as of Oct 21, 2026
IRON price chart
Powered by TradingViewWhat does Disc Medicine, Inc. do?
Disc Medicine Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It targets fundamental biological pathways associated with the formation and function of red blood cells, particularly heme biosynthesis and iron homeostasis, to address unmet needs in blood disorders. The company's pipeline features bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria, X-linked protoporphyria, and Diamond-Blackfan Anemia; DISC-0974 for anemia in myelofibrosis and chronic kidney disease; and DISC-3405 for polycythemia vera and related hematologic conditions. Preclinical efforts include DISC-0998. Operating in the biotechnology sector, Disc Medicine Inc. advances innovative therapies aimed at rare and chronic blood disorders, positioning it as a key player in hematology research and patient care. Founded in 2017 and headquartered in Watertown, Massachusetts, the company emphasizes turning scientific discoveries into effective medicines.